Finance entity
The 184-day window averages about 0.3 stories each week. The busiest single day carried 3. Against the same-window beat baseline of 26% negative, this entity's 0% share is less negative. markets accounts for 5 of the 8 tracked stories, while 2 other categories carry the remainder.
Last mentioned: Sep 15, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 38 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The 184-day window averages about 0.3 stories each week. The busiest single day carried 3. Against the same-window beat baseline of 26% negative, this entity's 0% share is less negative. markets accounts for 5 of the 8 tracked stories, while 2 other categories carry the remainder. FDA is the most frequent co-covered peer, appearing in 3 of the 8 tracked stories. Source depth averages 4.1 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 6 runs below the beat's 6.2 for that window. Moderna appears in 8 tracked Finance stories published from February 18, 2026 through August 20, 2026.
Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 4464 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Moderna. Shared-story counts are live from our verified record — not editorial picks.
Thursday Pre-Market
Key reports from Moderna, Newmont, Keurig Dr Pepper, Cheniere Energy, and Viatris.
FDA U-Turn
Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
Public Dispute
Moderna and administration officials engage in a public disagreement over the regulatory path forward.
Initial Rejection
Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.
For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
MarketBeat's August 19 high-volume value screen names Moderna, QQQ, Intel, Nebius, and SpaceX, while a large-cap screen adds SanDisk and Micron. The list highlights where dollar volume concentrated, but classifications include an ETF and a private company, so investors should validate the data before acting.
A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
A diverse slate of market leaders across semiconductors, consumer goods, and energy are set to report results, providing a critical pulse check on industrial demand and consumer spending. Key reports from Analog Devices, Moderna, and Kraft Heinz will highlight the divergent paths of the tech recovery and the healthcare sector's post-pandemic transition.
Source: Seeking Alpha · Seeking Alpha
Investors are navigating a complex Wednesday session as major players in biotech, semiconductors, and leisure release pivotal updates. Market attention is centered on Moderna's pipeline diversification and SanDisk's recovery in the memory sector, signaling a shift toward fundamental-driven trading.
The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Source: news8000.com · wlfi.com
YieldMax has announced its latest round of monthly distributions for its suite of single-stock synthetic covered call ETFs, including those tracking MicroStrategy, Tesla, and Microsoft. The payouts reflect the varying volatility levels of the underlying assets, with MRNA and MSTR leading the distribution amounts.
Source: Seeking Alpha · Seeking Alpha
The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
Moderna is linked from 8 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
